MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Total Assets 2011-2026 | NEOG
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.44 B | 4.55 B | 4.55 B | 993 M | 920 M | 797 M | 696 M | 618 M | 528 M | 452 M | 392 M | 345 M | 291 M | 252 M | 220 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.55 B | 220 M | 1.27 B |
Quarterly Total Assets Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 B | 3.38 B | 3.44 B | 4.04 B | 4.05 B | 4.5 B | 4.55 B | 4.58 B | 4.6 B | 4.56 B | 4.55 B | 4.51 B | 4.56 B | 977 M | 993 M | 981 M | 968 M | 932 M | 920 M | 920 M | 846 M | 822 M | 846 M | 774 M | 751 M | 721 M | 751 M | 721 M | 660 M | 641 M | 660 M | 641 M | 581 M | 547 M | 581 M | 547 M | 487 M | 469 M | 487 M | 469 M | 426 M | 409 M | 426 M | 409 M | 366 M | 358 M | 366 M | 358 M | 320 M | 308 M | 320 M | 308 M | 270 M | 261 M | 270 M | 261 M | 234 M | 228 M | 234 M | 228 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 B | 228 M | 1.35 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 24.33 | 5.28 % | $ 99.4 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M |  USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 23.41 | 0.47 % | $ 252 M |  China |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 39.7 | 0.92 % | $ 1.1 B | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 6.0 | -3.07 % | $ 176 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
6.26 B | $ 70.68 | 4.87 % | $ 27.3 B | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.58 | - | $ 2.01 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
1.49 B | $ 107.76 | -2.19 % | $ 13.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 145.25 | 2.96 % | $ 23.1 B | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 241.11 | -0.55 % | $ 43.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 20.41 | 19.15 % | $ 1.1 B | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 238.83 | 0.2 % | $ 175 B | USA |
 |
Celcuity
CELC
|
245 M | $ 104.34 | -2.95 % | $ 4.12 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 11.97 | -1.56 % | $ 340 M | Israel |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 3.19 | -5.62 % | $ 102 K | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 67.28 | -0.41 % | $ 4.66 B | USA |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 102.23 | 0.11 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 28.16 | 1.11 % | $ 851 M | USA |
 |
Medpace Holdings
MEDP
|
2.1 B | $ 599.7 | 0.79 % | $ 18.6 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
1.03 B | $ 6.56 | -0.3 % | $ 594 M | USA |
 |
Charles River Laboratories International
CRL
|
7.53 B | $ 219.73 | -0.62 % | $ 11.3 B | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
National Research Corporation
NRC
|
122 M | $ 20.3 | 2.94 % | $ 498 M | USA |
 |
Mettler-Toledo International
MTD
|
3.24 B | $ 1 486.95 | 0.1 % | $ 31.6 B |  Schweiz |
 |
Natera
NTRA
|
1.39 B | $ 233.65 | -0.28 % | $ 23 B | USA |
 |
ENDRA Life Sciences
NDRA
|
4.45 M | $ 4.51 | -3.01 % | $ 2.42 M | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 175.05 | 0.34 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 8.2 | 50.18 % | $ 1.06 B | USA |
 |
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 249.91 | -0.75 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 180.43 | -0.52 % | $ 14.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.29 B | $ 722.17 | 1.24 % | $ 59.6 B | USA |